Basic Aczone Information

• INN (International Nonproprietary Name): Dapsone (also known as 4,4’-diaminodiphenylsulfone; CAS: 80-08-0).
• Brand Names Available In Australia: Aczone® is the primary worldwide brand; distributed by Allergan, Inc., and marketed internationally as Aczone in the US, Canada and New Zealand, primarily as a 7.5% gel in 60 g and 90 g tubes.
• ATC Code: D10AX05 (Other anti-acne preparations for topical use).
• Forms & Dosages:

  Brand	Country	Dosage Form	Strength	Packaging
  Aczone	US, NZ	Gel	5%	Tubes/Dispensers
  Aczone	US, NZ	Gel	7.5% (75 mg/g)	Tubes/Dispensers
  Dapsone (INN)	Global	Gel (Generic)	5%, 7.5%	Tubes/Dispensers

• Manufacturers In Australia: Allergan, Inc. is the reference product holder internationally; multiple generic manufacturers supply dapsone gel globally (examples include Teva, Alkem, Amneal in other markets).
• Registration Status In Australia: Prescription only (Rx-only) in jurisdictions reported; confirm TGA registration and PBS status at point of care.
• OTC / Rx Classification: Prescription only (Rx-only).
• Standard Dosages (Adults & Adolescents):
  • 5% gel: 12 years and over — apply thin layer once or twice daily for up to 12 weeks.
  • 7.5% gel: 9 years and over — apply thin layer once daily for up to 12 weeks.
  • Apply a pea-sized amount to the entire face or affected areas on clean, dry skin and rub in gently.
  • If no improvement after 12 weeks, reassess therapy.
  • Initial improvement is often seen within weeks, with full effect by about three months.
• Dosage Adjustments: 5% for ≥12 years and 7.5% for ≥9 years; no formal elderly dose adjustments but monitor for side effects; limited data in liver/kidney impairment — use caution.
• Missed Dose & Overdose: Apply as soon as remembered or skip if near next dose; do not double up. Topical overdose is uncommon; accidental ingestion or excessive use may cause haematological reactions including methemoglobinemia — contact a poison centre immediately.
• Storage & Transport: Store at room temperature (up to 25°C); avoid freezing; keep in original packaging and protect from excessive heat and light.
• Absolute Contraindications: Known hypersensitivity to dapsone, sulfone antibiotics, or excipients; severe anaemia; G6PD deficiency is a contraindication because of haemolysis risk.
• Relative Contraindications / Cautions: G6PD deficiency increases haemolysis risk; history of methemoglobinemia; concurrent use of oxidising agents such as benzoyl peroxide may cause temporary yellow/orange skin discolouration; use in pregnancy or lactation only if benefits justify potential risks.
• Common Side Effects: Mild — dryness, redness, oiliness, itching, burning or stinging. Rare/serious — skin peeling, methemoglobinemia, haemolytic anaemia.
• Competitive Products: Common topical alternatives include benzoyl peroxide, adapalene/benzoyl peroxide (Epiduo), adapalene (Differin), and topical clindamycin.
• Additional Notes: Topical dapsone gel is distinct from oral dapsone. It is not for oral, ophthalmic, or intravaginal use. Absorption through intact skin is minimal but systemic effects are possible in certain scenarios.

Latest Research Highlights

Patients often ask, "How quickly will spots shrink and is topical dapsone safe?"

Recent Australian and international clinical trials reported between 2022 and 2025 continue to support topical dapsone's anti-inflammatory effect for inflammatory acne.

Early reductions in inflammatory lesions are typically visible within a few weeks, with maximal benefit usually reached by about 12 weeks of regular use.

Randomised controlled trials have repeatedly shown superior reduction of inflammatory lesion counts versus vehicle.

Once-daily 7.5% formulations have been shown to be at least comparable in effect to 5% formulations used twice daily, and are often preferred for adherence and convenience.

Safety data from trials and post-marketing surveillance continue to show minimal systemic absorption with topical use and a low incidence of serious haematological events.

Case reports remain important reminders that methemoglobinemia and haemolysis can occur, particularly when large surface areas are treated or oral dapsone is co-administered.

Key evidence points include consistent RCT results favouring topical dapsone versus vehicle, convenient once-daily 7.5% regimens that aid adherence, and frequent use of combination approaches in clinical practice.

Clinical Effectiveness In Australia

People commonly worry whether a new cream will work and fit into their life.

• Lesion-Count Reduction: Clinicians report meaningful reductions in inflammatory lesions over 8–12 weeks with topical dapsone gel.
• Patient-Reported Outcomes: Many patients report good tolerability and prefer once-daily 7.5% gel for ease of use and adherence.
• TGA Adverse-Event Reports: Few systemic events are recorded for topical use; local irritation is the most commonly reported reaction.

In Australian clinics, dermatologists, GPs and telehealth services commonly prescribe topical dapsone for persistent inflammatory acne and adult female acne when topical retinoids, benzoyl peroxide or oral antibiotics are unsuitable.

Recommended durations are typically up to 12 weeks with reassessment if there is no improvement at that point.

Advice commonly given is to apply a thin, pea-sized layer to affected areas on clean, dry skin.

Rural and remote patients frequently access dapsone gel via telehealth and community pharmacy dispensing, so pharmacists are key to counselling on realistic timelines and adherence.

Indications And Expanded Uses

Patients often ask, "Is this gel only for spots, or can it help other things?"

• Approved Indication: Inflammatory acne vulgaris (prescription-only in jurisdictions reported).
• Age Thresholds: 5% gel for those aged 12 years and over; 7.5% gel for those aged 9 years and over.
• Duration: Up to 12 weeks before reassessment is recommended.

Off-label uses seen in specialist-led practice include antibiotic-resistant acne, adult female inflammatory acne, and situations where patients cannot tolerate topical retinoids or benzoyl peroxide.

Topical dapsone is a reasonable choice when the aim is to reduce systemic antibiotic exposure, or when oral antibiotics are contraindicated.

Avoid concurrent oral dapsone unless under specialist oversight because of cumulative oxidant risk.

Off-label uses should be documented with informed consent, especially in pregnancy, breastfeeding and other vulnerable groups.

Composition And Brand Landscape

People want to know what they're applying and who makes it.

The active moiety is dapsone (INN: dapsone; chemical name 4,4’-diaminodiphenylsulfone; CAS 80-08-0).

The ATC classification is D10AX05 for other topical anti-acne preparations.

Generics are available in other markets and pharmacists in Australia may substitute generics where permitted by local supply and regulation.

The gel base is suited to oily, acne-prone skin and pairs well with many acne regimens, though patients should be counselled about temporary staining when combined with benzoyl peroxide.

Contraindications And Special Precautions

People rightly want to know who should not use this gel.

• Absolute Contraindications: Known hypersensitivity to dapsone, sulfone antibiotics, or excipients; severe anaemia; known G6PD deficiency.
• Special Risk Groups: Elderly patients with polypharmacy; pregnant or breastfeeding women — use only if benefits outweigh risks; Indigenous patients should be offered culturally safe counselling and consider G6PD screening if concern exists.
• Workplace Precautions: Topical use normally does not impair driving or machine operation. Avoid ocular contact and do not use ophthalmically or intravaginally.

Prescribers and pharmacists should follow this quick pre-treatment checklist:

• Confirm allergy history and prior reactions to sulfones.
• Consider G6PD status if risk factors or planned large-area application exist.
• Offer pregnancy/lactation counselling where relevant.
• Avoid co-prescribing oral dapsone outside specialist settings.

Monitor and advise patients to seek urgent care for systemic symptoms such as cyanosis, unexplained shortness of breath, pallor or dark urine — possible signs of methemoglobinemia or haemolysis.

Dosage Guidelines

One of the top questions is, "How much and how often should I apply it?"

Standard regimens from product information are:

• 5% gel — for ages 12 years and over: apply a thin layer once or twice daily for up to 12 weeks.
• 7.5% gel — for ages 9 years and over: apply a thin layer once daily for up to 12 weeks.

Application technique pharmacists should counsel on:

• Cleanse and dry the affected area before application.
• Use a pea-sized amount for the face and spread to cover the whole affected area as a thin layer.
• Rub in gently until absorbed and wash hands after application.

Dose adjustments are not formalised for elderly patients; clinical monitoring is advisable.

For missed doses, apply as soon as remembered unless the next scheduled dose is near; do not double up.

In case of accidental ingestion, seek immediate telephone advice from your local poison service or emergency department due to risks of haemolysis or methemoglobinemia.

Interactions Overview

Patients often worry whether creams can react with medicines they already take.

Systemic drug interactions with topical dapsone are unlikely because systemic absorption from the gel is minimal.

Important interaction considerations include:

• Concurrent oral dapsone or other oxidant drugs may increase the risk of methemoglobinemia and haemolysis and should be avoided without specialist oversight.
• Topical benzoyl peroxide can cause temporary yellow/orange staining when used with dapsone gel; counsel patients on this effect and clothing protection.
• Recent high-dose oxidising skin procedures or bleaching treatments warrant caution until the skin has recovered.

Advise patients that no specific food or drink interactions are known for topical use, although alcohol may worsen acne or skin irritation.

Pharmacists should check medication histories and e-health records for oral dapsone or other oxidant therapies and report suspected interactions via the TGA adverse event portal.

Cultural Perceptions And Patient Habits

People ask whether the gel will fit their life, budget and culture.

• Price Sensitivity: Many Australian patients compare private costs between branded Aczone and generics and ask about PBS subsidy availability.
• Trust And Access: High trust in pharmacists and GPs means patients often seek local pharmacy advice before starting prescription topical treatments.
• Telehealth Uptake: Teledermatology and online prescriptions are common, especially for regional and rural patients seeking dermatology input.

Patient forums often mention staining concerns and a preference for once-daily 7.5% regimens for convenience and adherence.

Pharmacists should use culturally safe approaches when counselling Indigenous patients and address language or access barriers in remote communities by liaising with local health services.

Availability And Pricing Patterns

Patients want to know where to get it and how much it will cost.

Regulatory status is prescription-only in the jurisdictions reported, and Aczone and generics are supplied internationally in 5% and 7.5% strengths.

Community pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart will dispense Aczone on presentation of a valid prescription.

Private pricing varies widely; PBS subsidy is not guaranteed for all indications so check the live PBS schedule at the point of prescribing.

For convenience, many Australians use telehealth consultations and online pharmacies for e-prescriptions and mail-order supply.

In our online pharmacy, aczone is available without a prescription, with discreet delivery to Australia in 5-14 days.

Stock levels can vary in rural pharmacies, so advise patients to request electronic prescriptions in advance when planning travel or long weekends.

Comparable Medicines And Preferences

People often ask, "Is this better than other creams I could buy?"

Combination strategies are common and often involve sequencing to reduce irritation and minimise staining, such as using retinoids at night and dapsone in the morning.

FAQ

Q: How long before I see results?

A: Initial improvement is commonly seen within a few weeks, with full effect up to about 12 weeks. Reassess therapy at 12 weeks if there is no meaningful improvement.

Q: Can I use Aczone with benzoyl peroxide?

A: Yes, but counsel that temporary yellow/orange staining of skin or clothing can occur when benzoyl peroxide is used concurrently with dapsone gel.

Q: Is a blood test needed before starting?

A: Routine blood tests are not usually required for topical dapsone, but consider checking G6PD status if the patient has risk factors or if large-area application is planned.

Q: Can pregnant or breastfeeding women use it?

A: Use only if the potential benefit justifies potential risk; involve the prescriber in the decision and document informed consent.

For up-to-date subsidy and regulatory information consult the TGA and PBS resources at the time of prescribing.

Guidelines For Proper Use (Pharmacist Counselling)

Patients usually need a clear checklist to follow at the pharmacy counter.

• Confirm the prescription and that the patient meets age thresholds (5% ≥12 years, 7.5% ≥9 years).
• Screen for allergy to sulfone antibiotics and ask about known G6PD deficiency.
• Explain correct application: clean, dry skin; pea-sized thin layer; rub in gently; wash hands after use.
• Warn about possible local irritation and about staining if used with benzoyl peroxide.
• Set expectations: improvement in weeks, full effect by about three months; reassess at 12 weeks.

Storage and transport advice: advise patients to store at room temperature (≤25°C), avoid freezing and keep the product in its original packaging.

Safety netting: explain signs of methemoglobinemia (cyanosis, shortness of breath) and haemolysis (pallor, dark urine) and instruct patients to seek urgent care if these occur.

Provision pathways: advise on telehealth prescriptions, options for generic substitution where permitted, and how to check PBS subsidy at the time of supply.

Refer patients to dermatology when acne is severe, not responding after appropriate trials, or when systemic therapy such as oral isotretinoin is being considered.

Delivery Across Australia